Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Venetoclax combined with three-day multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction treatment for patients with de novo acute leukaemias of ambiguous lineage

Xingli Zhao, Xiaohui SUO, Guanchen Bai, Yanliang Bai, Fang Zheng, Jie Liu, Ling Li, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 3451.

https://doi.org/10.1182/blood-2025-3451

Published: 2025

Journal Articles

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui SUO, Guanchen Bai, Yanliang Bai, Yunya Luo, Mei Lan, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Heng Li, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 3450.

https://doi.org/10.1182/blood-2025-3450

Published: 2025

Journal Articles

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion

Fang Zheng, Xiaohui SUO, Jie Liu, Liyun Zhao, Guanchen Bai, Xingli Zhao, Yanliang Bai, Dongmei Wang, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 3395.

https://doi.org/10.1182/blood-2025-3395

Published: 2025

Journal Articles

Fixed-dose inotuzumab ozogamicin combined with vincristine and prednisone regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia

Lei Ju, Guixi Liu, Jilei Zhang, Yuyu Liu, Lin Dong, Yan Guo, Xuemei Qin, Qiang Song, Jie Zou, Chenglu Yuan, Yan Shi, Dexiao Kong, Sifeng Gao, Yingchang Mi, Qingliang Teng, Jun Peng, Guanchen Bai

Blood (2025) 146 (Supplement 1): 1554.

https://doi.org/10.1182/blood-2025-1554

Published: 2025

Journal Articles

7-day venetoclax combined with intensive chemotherapy as induction treatment in newly diagnosed Acute Myeloid Leukemia with splicing factor gene mutations

Congcong Zhang, Xiaohui SUO, Xingli Zhao, Guanchen Bai, Yanliang Bai, Hongling Peng, Fang Zheng, Dongmei Wang, Liyun Zhao, ZePing Zhou, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 1618.

https://doi.org/10.1182/blood-2025-1618

Published: 2025

Journal Articles

7-day venetoclax combined with intensive chemotherapy as induction treatment in high-risk newly diagnosed Acute Myeloid Leukemia

Xiaohan Zhang, Xiaohui SUO, Guanchen Bai, Xingli Zhao, Yanliang Bai, Hongling Peng, Fang Zheng, Dongmei Wang, Liyun Zhao, ZePing Zhou, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 1617.

https://doi.org/10.1182/blood-2025-1617

Published: 2025

Journal Articles

Efficacy and safety results of TQB3909，a novel BCL-2 inhibitor, in combination with azacitidine for patients with myeloid malignancies

Jianxiang Wang, Guanchen Bai, Pengcheng He, Hao Jiang, Fuling Zhou, Wei Yang, Xingli Zhao, Shuning Wei, Zhen Wang, Wenwei Zhu, Lin Geng, Zhihua Zhang, Jianhua Qu, Jie Zhou, Tiejun Gong, Ligen Liu, Junfeng Zhu

Blood (2025) 146 (Supplement 1): 5196.

https://doi.org/10.1182/blood-2025-5196

Published: 2025

Journal Articles

Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui SUO, Guanchen Bai, Yanliang Bai, Yunya Luo, Mei Lan, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2025-1675

Published: 2025

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui Suo, Guanchen Bai, Yanliang Bai, Yunya Luo, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2024) 144 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2024-202430

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

Lei Ju, Xingli Zhao, Xiaohui Suo, ZePing Zhou, Yanliang Bai, Yunya Luo, Sifeng Gao, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Yaxian Tan, Guanchen Bai, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2024) 144 (Supplement 1): 1505.

https://doi.org/10.1182/blood-2024-202971

Published: 2024

Journal Articles

7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2024-198844

Published: 2024

Journal Articles

Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

Blood (2024) 144 (Supplement 1): 1485.

https://doi.org/10.1182/blood-2024-203422

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia：a Phase III, Prospective, Multicenter, Randomized Controlled Trial

Blood (2024) 144 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2024-202495

Published: 2024

Journal Articles

Venetoclax Combined with Homoharringtonine,Cytarabine and Aclacinomycin (HAAV) As Induction Therapy in Newly Diagnosed Young Adult Acute Myeloid Leukemia

Zepin Zhou, Xingli Zhao, Xiaohui Suo, Guanchen Bai, Zeyan Shi, Yunya Luo, Yaxian Tan, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Heng Li, Weihua Zhao, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2023) 142 (Supplement 1): 1517.

https://doi.org/10.1182/blood-2023-179275

Published: 2023

Journal Articles

Three-Day Decitabine Combined with Venetoclax in Patients with Newly Diagnosed or Relapsed/Refractory AML

Xiaohui Suo, Guanchen Bai, Xingli Zhao, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Xinxiao Lu, Linyu Yuan, Yingchang Mi, Kaiqi Liu

Blood (2023) 142 (Supplement 1): 5942.

https://doi.org/10.1182/blood-2023-181804

Published: 2023

Journal Articles

Venetoclax Combined with Homoharringtonine and Cytarabine ( HAV) As Induction Treatment in Elder or Intensive Chemotherapy (IC) Ineligible Patients with Newly Diagnosed Acute Myeloid Leukemia

Kaiqi Liu, Xiaohui Suo, Guanchen Bai, Zhangsong Yan, Yang Li, Bin Zhang, Jinsong He, Jiesi Li, Shuning Wei, Qiuling Li, Bo Hu, Yingchang Mi

Blood (2023) 142 (Supplement 1): 4272.

https://doi.org/10.1182/blood-2023-179009

Published: 2023

Journal Articles

Venetoclax Combined with Daunorubicin and Cytarabine (2 + 6) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Blood (2023) 142 (Supplement 1): 969.

https://doi.org/10.1182/blood-2023-179205

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Venetoclax combined with three-day multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction treatment for patients with de novo acute leukaemias of ambiguous lineage

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion

Fixed-dose inotuzumab ozogamicin combined with vincristine and prednisone regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia

7-day venetoclax combined with intensive chemotherapy as induction treatment in newly diagnosed Acute Myeloid Leukemia with splicing factor gene mutations

7-day venetoclax combined with intensive chemotherapy as induction treatment in high-risk newly diagnosed Acute Myeloid Leukemia

Efficacy and safety results of TQB3909，a novel BCL-2 inhibitor, in combination with azacitidine for patients with myeloid malignancies

Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia：a Phase III, Prospective, Multicenter, Randomized Controlled Trial

Venetoclax Combined with Homoharringtonine,Cytarabine and Aclacinomycin (HAAV) As Induction Therapy in Newly Diagnosed Young Adult Acute Myeloid Leukemia

Three-Day Decitabine Combined with Venetoclax in Patients with Newly Diagnosed or Relapsed/Refractory AML

Venetoclax Combined with Homoharringtonine and Cytarabine ( HAV) As Induction Treatment in Elder or Intensive Chemotherapy (IC) Ineligible Patients with Newly Diagnosed Acute Myeloid Leukemia

Venetoclax Combined with Daunorubicin and Cytarabine (2 + 6) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only